Zymeworks (ZYME) director granted 23,000 options and 15,400 RSUs

Rhea-AI Filing Summary

Zymeworks Inc. director Brian N. Cherry reported new equity awards granted on January 12, 2026. He received a stock option for 23,000 shares of common stock at an exercise price of $23.16 per share, vesting in 36 equal monthly installments starting one month after the grant date. He also received 15,400 restricted stock units (RSUs), each representing the right to receive one share of common stock upon vesting. These RSUs vest in three equal annual installments beginning on the first anniversary of the grant date. Both awards are reported as directly owned following the transactions.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Cherry Brian N

(Last) (First) (Middle)

C/O ZYMEWORKS INC.

108 PATRIOT DRIVE, SUITE A

(Street)

MIDDLETOWN DE 19709

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Zymeworks Inc. [ ZYME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/12/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$23.16	01/12/2026		A		23,000		(1)	01/11/2036	Common Stock	23,000	$0.00	23,000	D
Restricted Stock Unit	(2)	01/12/2026		A		15,400		(3)	(3)	Common Stock	15,400	$0.00	15,400	D

Explanation of Responses:

1. Stock options vest in 36 equal monthly installments starting one month after grant date of January 12, 2026.

2. Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of common stock.

3. RSUs vest in three equal annual installments beginning on first anniversary of grant date.

	/s/ Daniel Dex, Attorney-in-Fact	01/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ZYME director Brian N. Cherry report?

Brian N. Cherry, a director of Zymeworks Inc. (ZYME), reported receiving a stock option for 23,000 shares and 15,400 restricted stock units on January 12, 2026, both as new equity awards.

How many Zymeworks (ZYME) stock options did Brian N. Cherry receive?

He received a stock option covering 23,000 shares of Zymeworks common stock with an exercise price of $23.16 per share, reported as directly owned after the grant.

What are the vesting terms of Brian N. Cherry’s ZYME stock options?

The 23,000 stock options vest in 36 equal monthly installments, starting one month after the grant date of January 12, 2026, resulting in gradual monthly vesting over three years.

How many Zymeworks (ZYME) restricted stock units were granted to Brian N. Cherry?

He was granted 15,400 restricted stock units (RSUs), each representing the contingent right to receive one share of Zymeworks common stock upon vesting.

What is the vesting schedule for Brian N. Cherry’s ZYME RSUs?

The 15,400 RSUs vest in three equal annual installments, beginning on the first anniversary of the January 12, 2026 grant date.

Are Brian N. Cherry’s ZYME equity awards held directly or indirectly?

Both the 23,000 stock options and 15,400 RSUs are reported as directly owned by Brian N. Cherry, with no indirect ownership entity indicated.